Header Logo

Gabriel Pardo

TitleAssociate Member
InstitutionOklahoma Medical Research Foundation
DepartmentArthritis and Clinical Immunology
Addressn/a
825 N.E. 13th Street
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gawde S, Siebert N, Ruprecht K, Kumar G, Ko RM, Massey K, Guthridge JM, Mao-Draayer Y, Schindler P, Hastermann M, Pardo G, Paul F, Axtell RC. Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200268. PMID: 38885457; PMCID: PMC11186702.
      Citations:    Fields:    Translation:HumansCells
    2. Longobardi S, Lopez-Davis C, Khatri B, Georgescu C, Pritchett-Frazee C, Lawrence C, Rasmussen A, Radfar L, Scofield RH, Baer AN, Robinson SA, Darrah E, Axtell RC, Pardo G, Wren JD, Koelsch KA, Guthridge JM, James JA, Lessard CJ, Farris AD. Autoantibodies identify primary Sj?gren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B. Ann Rheum Dis. 2023 May 05. PMID: 37147113.
      Citations: 1     Fields:    Translation:Humans
    3. Gawde S, Agasing A, Bhatt N, Toliver M, Kumar G, Massey K, Nguyen A, Mao-Draayer Y, Macwana S, DeJager W, Guthridge JM, Pardo G, Dunn J, Axtell RC. Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022 Jul; 63:103922. PMID: 35671674.
      Citations: 4     Fields:    Translation:Humans
    4. Pardo G, Pineda ED, Ng CD, Sheinson D, Bonine NG. The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis. J Health Econ Outcomes Res. 2022; 9(1):111-116. PMID: 35586512.
      Citations: 3     
    5. Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG. Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis. Neurol Ther. 2022 Mar; 11(1):337-351. PMID: 35020156.
      Citations: 5     
    6. Miller BJ, Kolobe TH, Larson RD, Pribble BA, Pardo G, James SA. Functional intermuscular reduction in spasticity for people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211061547. PMID: 35024159.
      Citations:    
    7. Pardo G, Coates S, Okuda DT. Outcome measures assisting treatment optimization in multiple sclerosis. J Neurol. 2022 Mar; 269(3):1282-1297. PMID: 34338857.
      Citations: 2     Fields:    Translation:Humans
    8. Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649. PMID: 33624535.
      Citations: 13     Fields:    Translation:Humans
    9. Bermel RA, Waubant E, Pardo G, Bass A, Repovic P, Newsome S, Lindsey JW, Kile D, Pradhan A, Musch B, Zabeti A. Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Ann Clin Transl Neurol. 2021 03; 8(3):711-715. PMID: 33621404.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    10. Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454. PMID: 33045496.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    11. Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernández Ó, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353. PMID: 32583052.
      Citations: 18     Fields:    Translation:Humans
    12. Cantrell GS, Lantis DJ, Bemben MG, Black CD, Larson DJ, Pardo G, Fjeldstad-Pardo C, Larson RD. Relationship between soleus H-reflex asymmetry and postural control in multiple sclerosis. Disabil Rehabil. 2022 Feb; 44(4):542-548. PMID: 32525405.
      Citations: 3     Fields:    Translation:Humans
    13. Farrell JW, Bemben DA, Black CD, Larson DJ, Pardo G, Fjeldstad-Pardo C, Larson RD. Evaluation of Power Production Asymmetry during Cycling in Persons with Multiple Sclerosis. Int J Environ Res Public Health. 2019 09 17; 16(18). PMID: 31533224.
      Citations: 1     Fields:    Translation:Humans
    14. Jog NR, McClain MT, Heinlen LD, Gross T, Towner R, Guthridge JM, Axtell RC, Pardo G, Harley JB, James JA. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 2020 01; 106:102332. PMID: 31515129.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    15. Perrone CM, Lisak RP, Meltzer EI, Sguigna P, Tizazu E, Jacobs D, Melamed E, Lucas A, Freeman L, Pardo G, Goodman A, Fox EJ, Costello K, Parsons MS, Zamvil SS, Frohman EM, Frohman TC. Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2019 07; 6(4):e582. PMID: 31355318.
      Citations:    Fields:    Translation:Humans
    16. Freitas EDS, Frederiksen C, Miller RM, Heishman A, Anderson M, Pardo G, Fjeldstad C, Bemben DA, Bemben MG. Acute and Chronic Effects of Whole-Body Vibration on Balance, Postural Stability, and Mobility in Women With Multiple Sclerosis. Dose Response. 2018 Oct-Dec; 16(4):1559325818816577. PMID: 30627068.
      Citations: 5     
    17. Fjeldstad-Pardo C, Thiessen A, Pardo G. Telerehabilitation in Multiple Sclerosis: Results of a Randomized Feasibility and Efficacy Pilot Study. Int J Telerehabil. 2018; 10(2):55-64. PMID: 30588276.
      Citations: 5     
    18. Husain F, Pardo G, Rabadi M. Headache and Its Management in Patients With Multiple Sclerosis. Curr Treat Options Neurol. 2018 Mar 24; 20(4):10. PMID: 29574601.
      Citations: 10     
    19. Pardo G, Jones DE. Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017 12; 264(12):2375-2377. PMID: 29063239.
      Citations:    Fields:    
    20. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017 Dec; 264(12):2351-2374. PMID: 28879412.
      Citations: 47     Fields:    Translation:Humans
    21. Fjeldstad C, Pardo G. Immediate Effect of a Service Dog on Walking Speed in Individuals with Multiple Sclerosis and Gait Dysfunction: A Pilot Study. Int J MS Care. 2017 Jan-Feb; 19(1):40-41. PMID: 28243185.
      Citations: 1     
    22. Fjeldstad C, Suárez G, Klingler M, Henney HR, Rabinowicz AL, Pardo G. Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. Int J MS Care. 2015 Nov-Dec; 17(6):275-83. PMID: 26664333.
      Citations:    
    23. Fjeldstad C, Fjeldstad AS, Pardo G. Use of Accelerometers to Measure Real-Life Physical Activity in Ambulatory Individuals with Multiple Sclerosis: A Pilot Study. Int J MS Care. 2015 Sep-Oct; 17(5):215-20. PMID: 26472942.
      Citations: 11     
    24. Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR, Blight AR, Carrazana EJ. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. Int J MS Care. 2015 May-Jun; 17(3):138-45. PMID: 26052259.
      Citations: 5     
    25. Schubert RD, Hu Y, Kumar G, Szeto S, Abraham P, Winderl J, Guthridge JM, Pardo G, Dunn J, Steinman L, Axtell RC. IFN-ß treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015 Mar 01; 194(5):2110-6. PMID: 25646307.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    26. Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15; 341(1-2):22-7. PMID: 24731783.
      Citations: 36     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    27. Fjeldstad C, Fjeldstad AS, Weir JP, Pardo G. Association of vitamin D deficiency with RNFL thickness in MS individuals without history of optic neuritis. Mult Scler Relat Disord. 2014 Jul; 3(4):489-93. PMID: 25877061.
      Citations: 2     Fields:    
    28. Fjeldstad C, Bemben M, Pardo G. Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography. J Clin Neurosci. 2011 Nov; 18(11):1469-72. PMID: 21917458.
      Citations: 22     Fields:    Translation:HumansCells
    29. Fjeldstad C, Pardo G, Bemben D, Bemben M. Decreased postural balance in multiple sclerosis patients with low disability. Int J Rehabil Res. 2011 Mar; 34(1):53-8. PMID: 20679901.
      Citations: 22     Fields:    Translation:Humans
    30. Zwibel H, Pardo G, Smith S, Denney D, Oleen-Burkey M. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol. 2011 Mar; 258(3):402-11. PMID: 20922405.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    31. Pardo G, Boutwell C, Conner J, Denney D, Oleen-Burkey M. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. J Neurosci Nurs. 2010 Feb; 42(1):40-6. PMID: 20187348.
      Citations: 7     Fields:    Translation:Humans
    32. Fjeldstad C, Frederiksen C, Fjeldstad AS, Bemben M, Pardo G. Arterial compliance in multiple sclerosis: a pilot study. Angiology. 2010 Feb-Mar; 61(1):31-6. PMID: 19497928.
      Citations: 4     Fields:    Translation:Humans
    33. Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007 Jun; 29(6):1128-45. PMID: 17692727.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    34. Pardo G. Neuroophthalmological manifestations of diabetes mellitus. Int Ophthalmol Clin. 1998; 38(2):213-26. PMID: 9604748.
      Citations: 1     Fields:    Translation:Humans
    Pardo's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (118)
    Explore
    _
    Co-Authors (15)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _